Swedish real-world health data, a recent addition to the in-house capabilities of Medaffcon, offer unique possibilities for measuring disease burdens and determinants, the effects of different exposures, and the outcomes of various health conditions in a population of almost 10.5 million people.
The Nordics, with their exceptional data sources and infrastructure, are clear forerunners in the real-world data and evidence landscape. By leveraging its access and understanding of the high-quality healthcare services, massive digital data repositories, and research-supportive operating environment in the Nordics, Medaffcon is uniquely positioned to be a reliable and valuable partner for organisations eager to utilise healthcare data for research and product development.
The permit processes for Swedish data tend to be smooth. The Swedish Ethical Review Authority typically assesses the application within 60 days. Once received, the data can be applied from the data owner and utilised for future projects if they fall within the parameters defined in the granted ethical permit, are started within two years from receiving the permit, and their results are published.
“That’s precisely what we’ve done in several of our larger projects. With a single well-covered ethical application and detailed data application, we’ve been able to maximise data use and answer clinically important research questions in up to 20 publications,” reveals Medaffcon’s lead RWE specialist, Dr. Johanna Simin, PhD MSc, a clinical epidemiologist with a PhD from the Karolinska Institute in Stockholm.
Medaffcon’s dedicated team of RWE and Data Analysts can handle all aspects of your RWE project, from design and project management to analytics and publications. Whether you need end-to-end support or assistance with specific parts of your RWE needs, we have the capabilities and flexibility to meet your requirements.
Medaffcon has a track record of nearly 10 years of RWE solutions. We have done 35 RWE Publications in these years, and we have delivered over 360 projects to leading pharma companies in 2022-2023. To learn more about our expertise and the projects we have successfully delivered to leading pharma companies over the past 10 years, please visit our website and explore our selected publications.
Medaffcon answers call for its solutions-oriented data approach in Sweden
Medaffcon unlocks new research opportunities with Swedish real-world health data
The lymphoma research project has proven to be an exceptionally versatile source of new knowledge. The project includes at least two doctoral researchers, and its results are expected to generate well over ten scientific articles.
5th Nordic RWE and AI conference is organized by University of Helsinki and Åbo Akademi University. Register to the event here!
Despite its high-risk nature and availability of kidney treatments, chronic kidney disease (CKD) often goes undiagnosed. This especially concerns patients without type 2 diabetes (T2D), who represent the majority of CKD patients. This finding comes from a recent registry study published in Nephrology Dialysis Transplantation (NDT).
Country Director Sweden
M.Sc (Econ.) & M.Sc (Health Econ)
+46 73 447 47 27
lisse-lotte.hermansson@medaffcon.se
Lisse-Lotte started at Medaffcon 1st of October 2024. Previously she was at a Swedish-German company as CSO Chief Scientific Officer, consulting European companies about Nordic health data opportunities and market access. She has a M.Sc (Econ.) from Helsingin School of Economics and a M.Sc (Health Econ) from Karolinska. Additionally a Ph.D student at the University of Turku in Health Economics. She has obtained a long experience from global pharma and medtech. She has lived over 20 years in Sweden.
The current development gives new possibilities to utilise data. With AI we can produce synthetic data and build digital twins that can actually support drug development and support healthcare providers. Innovative solutions are only useful if they are adopted to daily practice.
Old ways of working will vanish and RWD will be acknowledged as an excellent option or support for RCTs. As RWD is enabling more cost-effective evidence generation for new treatments. Treatments need to be more personalised so that the right drugs, diagnostics and devices are used for the right patients at the right time.